Citigroup’s Y-mAbs Therapeutics YMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$68.8K Sell
15,250
-13,268
-47% -$59.8K ﹤0.01% 3881
2025
Q1
$126K Sell
28,518
-20,713
-42% -$91.8K ﹤0.01% 3701
2024
Q4
$385K Buy
49,231
+21,872
+80% +$171K ﹤0.01% 3190
2024
Q3
$360K Buy
27,359
+18,390
+205% +$242K ﹤0.01% 3194
2024
Q2
$108K Buy
8,969
+2,224
+33% +$26.9K ﹤0.01% 3452
2024
Q1
$110K Buy
6,745
+734
+12% +$11.9K ﹤0.01% 3519
2023
Q4
$41K Buy
6,011
+5,992
+31,537% +$40.9K ﹤0.01% 3877
2023
Q3
$103 Sell
19
-10,936
-100% -$59.3K ﹤0.01% 4640
2023
Q2
$74.4K Sell
10,955
-35,887
-77% -$244K ﹤0.01% 3723
2023
Q1
$235K Buy
46,842
+45,779
+4,307% +$229K ﹤0.01% 3035
2022
Q4
$5.19K Sell
1,063
-93,217
-99% -$455K ﹤0.01% 4297
2022
Q3
$1.36M Buy
94,280
+35,354
+60% +$510K ﹤0.01% 1883
2022
Q2
$891K Buy
58,926
+28,524
+94% +$431K ﹤0.01% 2164
2022
Q1
$361K Sell
30,402
-37,353
-55% -$444K ﹤0.01% 3060
2021
Q4
$1.1M Buy
67,755
+35,999
+113% +$583K ﹤0.01% 2450
2021
Q3
$906K Sell
31,756
-41,546
-57% -$1.19M ﹤0.01% 2463
2021
Q2
$2.48M Sell
73,302
-23,651
-24% -$800K ﹤0.01% 1946
2021
Q1
$2.93M Buy
96,953
+88,812
+1,091% +$2.69M ﹤0.01% 1700
2020
Q4
$403K Buy
8,141
+4,712
+137% +$233K ﹤0.01% 2777
2020
Q3
$132K Sell
3,429
-13,651
-80% -$525K ﹤0.01% 2994
2020
Q2
$738K Buy
17,080
+570
+3% +$24.6K ﹤0.01% 2319
2020
Q1
$431K Sell
16,510
-1,061
-6% -$27.7K ﹤0.01% 2368
2019
Q4
$549K Buy
17,571
+16,276
+1,257% +$509K ﹤0.01% 2590
2019
Q3
$34K Sell
1,295
-5,249
-80% -$138K ﹤0.01% 3974
2019
Q2
$150K Buy
6,544
+4,685
+252% +$107K ﹤0.01% 3375
2019
Q1
$49K Buy
1,859
+25
+1% +$659 ﹤0.01% 4037
2018
Q4
$37K Buy
+1,834
New +$37K ﹤0.01% 4101